Manuscripts, Posters, and Presentations

Adherence

Emergency Room Visits, Lost Time and Productivity Costs in Employees with Coronary Artery Disease Are Impacted by Medication Adherence

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Major Depressive Disorder

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes, Depression, and Coronary Artery Disease

The Impact of Major Depressive Disorder and Suicidal Ideation or Suicide Attempts on Caregivers: A Comparison of Direct and Indirect Costs Using Objectively Measured Real-world Data

The Impact of Major Depressive Disorder and Suicidal Ideation or Suicide Attempts on Caregivers: A Comparison of Direct and Indirect Costs Using Objectively Measured Real-world Data

Changes in Mental Health-Related Insurance Claims Costs Among Patients Treated for Bipolar Disorder

Medication Adherence and the Direct Medical and Prescription Cost Impact of Fixed vs Loose Dose Thiazolidinedione Combination Products Among Type 2 Diabetes Patients

Medication adherence with Disease modifying treatments for multiple sclerosis: Findings from a US National database of employees

Medication Possession Ratio and Health Benefit Cost Comparisons in Type 2 Diabetic Patients using Fixed and Loose Dose Thiazolidinedione Combination Products. Presented at the American Diabetes Association Annual Meeting June 7-9, 2008, San Francisco, CA.

Persistence with Leuprolide Acetate in patients with Prostate Cancer

AHRQ

Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder

Comorbidities during the year following diagnosis for persons with and without GERD using the Agency for Health Research and Quality (AHRQ) 261 Specific Categories

Objective Costs and Prevalence of Comorbidities for Persons with and without Insomnia

Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of AHRQ 261 Specific Categories

Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of Major Diagnostic Categories

Prevalence and Costs of Comorbidities Among Persons with and without Multiple Sclerosis: An Analysis of the AHRQ Major and Specific Diagnostic Categories

Prevalence, Costs and Services of Comorbid conditions associated with Functional Dyspepsia

The Likelihood of Having Functional Dyspepsia Based on Other Comorbid Conditions

The Prevalence and Costs to Treat Comorbidities in Persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months After Diagnosis: An Employer Perspective

The Prevalence and Costs to Treat GI Comorbidities in Persons with Constipation The American College of Gastroenterology Annual Scientific Meeting

Asthma

An employer perspective on annual employee and dependent costs for pediatric asthma

Back Pain

Self-reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders

Self-reported and objectively measured productivity and absence costs for employees with back and joint disorders

Self-reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders

Caregiver Trends in Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Back Pain in the United States

Trends in Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Back Pain in the United States

Work Absence and Absence Costs in Patients with Osteoarthritis (OA) and Low Back Pain (LBP) in the United States

Biologic

Biologic, Biosimilar and Specialty Drug Utilization Trends Among US Employers

Biosimilars

Biosimilar Benefit Use, Adoption, and Conversions

Biologic, Biosimilar and Specialty Drug Utilization Trends Among US Employers

Biosimilar adoption, benefit-use claims & dollars

Factors influencing the economics of biosimilars in the US.

Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Management of Specialty Pharmacies, Specialty and Biosimilar products 

The 2018 US Payor Landscape: Trends and Results from Formulary Management Surveys

Cancer

A Holistic Overview of the Real Costs of Cancer on Patients (Panel Discussion at the AVBCC [Association for Value Based Cancer Care])

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employees with Breast, Skin, GI, Female, Male, and “Other” Cancers

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee “Caregivers” of Patients with Breast, Skin, GI, Female, Male, and “Other” Cancers

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Cancer

Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees With Cancer Conditions in the United States

Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees Whose Spouses have Cancer Conditions in the United States

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Cancer

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee “Caregivers” of Patients with Breast, Skin, GI, Female, Male, and “Other” Cancers

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employees with Breast, Skin, GI, Female, Male, and “Other” Cancers

Caregiver Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Cancer in the United States

Prevalence and Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Cancer

Cancer caregiver absence cost and lost time

2018 Cancer Concerns of United States Health Plans

Persistence with Leuprolide Acetate in patients with Prostate Cancer

United States Health Plan Cancer Concerns in 2018

Cardiovascular

Exploration of Reason Codes in Real World Cardiovascular System Short-term Disability Claims in the United States

Exploration of Reason Codes in Real World Cardiovascular System Short-Term Disability Claims in the United States

Emergency Room Visits, Lost Time and Productivity Costs in Employees with Coronary Artery Disease Are Impacted by Medication Adherence

Absence Time and Payments due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Circulatory Disorders in the United States

Caregiver

An employer perspective on annual employee and dependent costs for pediatric asthma

The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee “Caregivers” of Patients with Breast, Skin, GI, Female, Male, and “Other” Cancers

Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees Whose Spouses have Cancer Conditions in the United States

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee “Caregivers” of Patients with Breast, Skin, GI, Female, Male, and “Other” Cancers

Caregiver Trends in Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Back Pain in the United States

Caregiver Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Mental Disorders in the United States

Caregiver Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Cancer in the United States

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Cancer caregiver absence cost and lost time

Direct and Indirect Costs Among Caregivers of Patients With Major Depressive Disorder and Suicidal Ideation or Suicidal Attempt

Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database

Circulatory

Absence Time and Payments due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Circulatory Disorders in the United States

Constipation

Functional gastrointestinal disorder comorbidities: Comparisons of prevalence and costs in the 6 months before and after diagnoses of constipation (C) and irritable bowel syndrome and constipation (IBS+C)

Direct cost similarities by point of service for persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An employer perspective

Covid

Predicting New Mental Health Cases Pre- vs. Post COVID-19: A Comparison of Medical-Only and Integrated Data

Dermatology

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Skin Conditions in the United States

Devices

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Health Plan Coverage for Medical Devices and the Use of Electronic Medical Record Systems

Diabetes

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes

Prevalence and Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Diabetes

Diagnostics

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Specialty Pharmacy, Diagnostic and Genetic Testing Coverage in US Health Plans: Results from a Survey of Medical and Pharmacy Directors

United States Health Plan Cancer Concerns in 2018

Digital Health

Survey Results of Contemporary US Health Plan Policies – Affordable Care Act (ACA), Digital Technologies, Value Based Contracting (VBC) and Comparative Effectiveness Research (CER)

Editorial

Factors influencing the economics of biosimilars in the US.

Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?

Specialty pharmaceuticals and the quest for better outcomes

EMRs / EHRs

Health Plan Coverage for Medical Devices and the Use of Electronic Medical Record Systems

Endocrinology

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes

Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Non-Diabetic Endocrine Disorders in the United States

Health Benefit Costs and Absenteeism Among Employed Patients With Acromegaly

Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care

Prevalence and Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Diabetes

Healthcare services utilization and costs associated with the management of patients living with acromegaly

Acromegaly significantly impacts employees’ health benefit costs and increases work absenteeism

United States comparative costs and absenteeism of diabetic ophthalmic conditions

Comparative Health Benefit Costs of Employees with Diabetic Macular Edema, Diabetic Retinopathy, or Diabetes Versus No Diabetes in the United States

How Does Diabetic Eye Disease Affect the American Worker?

Impact of Rheumatoid Arthritis on Health Care Costs and Work Productivity: A Comparative Assessment With Diabetes and Depression 

Medication Adherence and the Direct Medical and Prescription Cost Impact of Fixed vs Loose Dose Thiazolidinedione Combination Products Among Type 2 Diabetes Patients

Medication Possession Ratio and Health Benefit Cost Comparisons in Type 2 Diabetic Patients using Fixed and Loose Dose Thiazolidinedione Combination Products. Presented at the American Diabetes Association Annual Meeting June 7-9, 2008, San Francisco, CA.

Progression to Adjunctive Therapy among Commercially-Insured Patients with Partial Onset Epilepsy. 67th Annual Meeting of the American Academy of Neurology, April 18

Epilepsy

Comparisons of the Health Benefit Costs Among Monotherapy and Adjunctive Therapy Patients with Epilepsy and Their Employed Spouses

Comparisons of the utilization, costs, and services by location of care for employees whose spouses with epilepsy have partial onset seizures and are managed by monotherapy or adjunctive therapy.

Facioscapulohumeral Muscular Dystrophy

Sex-related Utilization Differences in the 12-months After a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD) Age-Related Differences in Management Among Patients Over and Under 40 Years

Facioscapulohumeral Muscular Dystrophy (FSHD) Mobility Aids and Healthcare Utilization After Diagnosis from a Real-World Data Analysis

Prescription Medication Use Prior to and Following a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): Learnings from the Patient Journey

Inpatient Admissions and Emergency Department Visits for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis of Pre- and Post-Diagnosis Events

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Understanding the Patients’ Journey to the Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Prescription medications during patients’ journey to the diagnosis of facioscapulohumeral muscular dystrophy: a real-world retrospective data analysis

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Family Medical Leaves

Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among US Employees

Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among United States Employees

Functional Dyspepsia

Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs

Gastroenterology

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Digestive System (Gastrointestinal) Conditions in the United States

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database

Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD

Cost of illness to the employer of Gastroesophageal Reflux Disease (GERD): Comparison of medical, pharmacy, sick leave, short- and long-term disability, and workers’ compensation claims and medical claims by place of service between employees with and without GERD

Costs and absence of HCV-infected employees by disease stage

Costs of Functional Dyspepsia—Results from a large US Employer Database

Direct costs by point of service for persons with and without constipation: An employer perspective

Healthcare Cost Comparisons by Point of Service for Persons With or Without Constipation.

Impact of the ROME II criteria – assessment of related comorbid prevalence and costs of patients with functional dyspepsia

Incremental Sick Leave Costs and Lost Time Among Employees with Psychiatric and Medical Conditions

Medical, Pharmacy, and Sick Leave Costs for Constipation and for Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An Employer Perspective

The Prevalence and Costs to Treat GI Comorbidities in Persons with Constipation The American College of Gastroenterology Annual Scientific Meeting

Objective Measurement of Productivity While at Work in US Employees with and without Gastroesophageal Reflux Disease (GERD)

The Direct and Indirect Costs of Employees with Hepatitis C Vary by Stage of Disease. Presented at Academy Health’s 2014 Annual Research Meeting

Prevalence, Costs and Services of Comorbid conditions associated with Functional Dyspepsia

Retrospective Analysis of Switching from a Twice-Daily Proton Pump Inhibitor to Once-Daily Esomeprazole

Similarities between Constipation with and without Irritable Bowel Syndrome in a Medicaid population: Costs trends by category in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data

The Impact of Hepatitis-C Viral (HCV) Treatment on Work Absence and Productivity

The Likelihood of Having Functional Dyspepsia Based on Other Comorbid Conditions

The Prevalence and Costs to Treat Comorbidities in Persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months After Diagnosis: An Employer Perspective

Comorbidities during the year following diagnosis for persons with and without GERD using the Agency for Health Research and Quality (AHRQ) 261 Specific Categories

Cost of gastro-oesophageal reflux disease to the employer: a US perspective

Excess Comorbidity Prevalence and Cost Associated with Functional Dyspepsia in an Employed Population

Functional Dyspepsia Impacts Absenteeism and Direct and Indirect Costs

Functional gastrointestinal disorder comorbidities: Comparisons of prevalence and costs in the 6 months before and after diagnoses of constipation (C) and irritable bowel syndrome and constipation (IBS+C)

Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease

Direct cost similarities by point of service for persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An employer perspective

Annual Direct and Indirect Cost of Illness in Employees with Irritable Bowel Syndrome plus Constipation

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

Assessment of Work Absences Associated with Constipation

Cost, Absences, Prevalence and Impact of Bipolar Disorder, Other Mental Disorders, Chronic Constipation, Functional Dyspepsia, Gastroesophageal Reflux Disease, Gout, And Insomnia. (AMCP)

Comparison of the Medication Possession Ratio Alone and in Combination with Breakthrough Events for Classifying Patients with Acid-Related Diseases

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. (ISPOR)

Constipation in a Medicaid population: Trends in prevalence, age, gender, and costs in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data

Cost estimates of chronic constipation in California Medicaid (Medi-Cal) patients

Cost of Illness for Constipation: Medical, Pharmacy, and Work Absence Costs in Employees With or Without Constipation

Cost of illness of Gastroesophageal Reflux Disease (GERD): Comparison of medical, pharmacy, sick leave, short- and long-term disability, and workers’ compensation claims and medical claims by place of service between employees with and without GERD (DDW)

GERD

Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease

Headache

Real World Objectively Measured Productivity Losses of Employees with Migraines and the Use of Calcitonin Gene-Related Peptide Inhibitors (CGRPis) in United States Employees

Characterizing Use and Productivity Losses Among United States Employees with Migraines Using Calcitonin Gene-Related Peptide inhibitors (CGRPis): 2017-2022

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Absence Benefit Utilization, Duration of Leaves, and Payments Vary By Benefit and over Time for Short- and Long-Term Disability and Workers’ Compensation for Employees with Headaches and Migraines in the United States

Hepatology

Analyzing Data for Specialty Conditions Such as Hepatitis-C

The Size Paradox: Comprehensive Data and Better Methods Can Yield Significant Results with Smaller Sample Sizes in Real World Data (Size Doesn’t Always Matter)

The Size Paradox: Comprehensive Data and Better Methods Can Yield Significant Results with Smaller Sample Sizes in Real World Data (Size Doesn’t Always Matter)

Absenteeism and Productivity Among Employees Being Treated for Hepatitis C

The Impact of Hepatitis-C Viral (HCV) Infection on Work Absence, Productivity, and Healthcare Benefit Costs

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

Comparison of Direct Medical Costs and Services by Point of Service and Prescription Cost for Persons With Hepatitis-C With and Without Treatment

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. (ISPOR)

Costs and absence of HCV-infected employees by disease stage

Employees Living with Human Immunodeficiency Virus (HIV): Impact of Disease and Antiretroviral Therapies on Healthcare Costs and Productivity

The Direct and Indirect Costs of Employees with Hepatitis C Vary by Stage of Disease. Presented at Academy Health’s 2014 Annual Research Meeting

The Impact of Hepatitis-C Viral (HCV) Treatment on Work Absence and Productivity

HIV

Employees Living with Human Immunodeficiency Virus (HIV): Impact of Disease and Antiretroviral Therapies on Healthcare Costs and Productivity

IBS

Functional gastrointestinal disorder comorbidities: Comparisons of prevalence and costs in the 6 months before and after diagnoses of constipation (C) and irritable bowel syndrome and constipation (IBS+C)

Direct cost similarities by point of service for persons with Constipation and Irritable Bowel Syndrome with Constipation in the 6 Months Before and After Diagnosis: An employer perspective

Infertility

The Impact of Health Benefit Design on Assisted Reproductive Technology (ART) Utilization and Pregnancy-Related Outcomes

IVR

Multilingual Interactive Voice Response System for Patient Reported Outcomes in Multiple Countries

Managed Care

Observations from U.S. Payors Today and Predictions for the Future

The 2015 US Payor Landscape: Results from a Survey of Medical and Pharmacy Directors on Formulary Management

The 2018 US Payor Landscape: Trends and Results from Formulary Management Surveys

Mental Health

Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes

Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes

Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among US Employees

Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among United States Employees

Utilization of Short-Term and Long-Term Disability, and Workers’ Compensation in Employees with Major Depressive Disorder Compared with Employed Controls

The Cost of Suicide Attempts to Employers: Medical and Prescription Claims for Employees, Spouses, and Adult Dependents

Caregiver Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Mental Disorders in the United States

Predicting New Mental Health Cases Pre- vs. Post COVID-19: A Comparison of Medical-Only and Integrated Data

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Major Depressive Disorder

Integrated Data Models Outperform Direct Claims Only Models in Predicting New Mental Health Cases

Disability and workers’ compensation trends for employees with mental disorders and SUDs in the United States

Direct and Indirect Costs Among Caregivers of Patients With Major Depressive Disorder and Suicidal Ideation or Suicidal Attempt

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Substance Abuse Mental Disorders in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Mental Disorders in the United States

The Impact of Major Depressive Disorder and Suicidal Ideation or Suicide Attempts on Caregivers: A Comparison of Direct and Indirect Costs Using Objectively Measured Real-world Data

The Impact of Major Depressive Disorder and Suicidal Ideation or Suicide Attempts on Caregivers: A Comparison of Direct and Indirect Costs Using Objectively Measured Real-world Data

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database

Changes in Mental Health-Related Insurance Claims Costs Among Patients Treated for Bipolar Disorder

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Costs of physical and mental comorbidities among employees: a comparison of those with and without bipolar disorder

Employee costs before and after treatment initiation for bipolar disorder

Incurring Greater Health Care Costs: Risk Stratification of Bipolar Disorder Employees

Lost time, absence costs, and reduced productivity output for employees with bipolar disorder

The economic impact of bipolar disorder in an employed population from an employer perspective

Annual Direct and Indirect Costs of Employees with Bipolar Disorders, Schizophrenia, and Controls from 2001 to 2011

Annual Direct and Indirect Costs of US Employees with Bipolar Disorders, Schizophrenia and Controls from 2001 to 2011

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

Annual Total Medical Costs For Bipolar Disorder Patients Treated With Antipsychotics

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees

Direct and Indirect Costs Among US Employees with and without Bipolar Disorder or Schizophrenia: Annual Cost Trends from 2001 to 2011

Impact of Rheumatoid Arthritis on Health Care Costs and Work Productivity: A Comparative Assessment With Diabetes and Depression 

Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees.

Incremental Health Benefits Cost of Bipolar Disorder among Insured Employees

Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of Major Diagnostic Categories

Physical and Mental Comorbidities among Employees with Bipolar Disorder: Analysis of AHRQ 261 Specific Categories

Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD

Lost Work Days and Emergency Department Visits among Patients Treated for Bipolar Disorder

Logistic Regression to Identify the Factors Predicting the Likelihood of Lurasidone Initiation in a US Employer Database.

Likelihood of employment termination for employees with Bipolar Disorder treated with different psychotropic Medications

Incremental Sick Leave Costs and Lost Time Among Employees with Psychiatric and Medical Conditions

Methodology

Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes

Self-reported and objectively measured productivity and absence costs for employees with back and joint disorders

Predicting New Mental Health Cases Pre- vs. Post COVID-19: A Comparison of Medical-Only and Integrated Data

Absence Benefit Use and Payment Trends Among Short- and Long-Term Disability and Workers’ Compensation for Employees with the Top 20 Agency for Healthcare Research and Quality Conditions in the United States

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes, Depression, and Coronary Artery Disease

Integrated Data Models Outperform Direct Claims Only Models in Predicting New Mental Health Cases

Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective

Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective

Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective

Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives

Comparison of the Medication Possession Ratio Alone and in Combination with Breakthrough Events for Classifying Patients with Acid-Related Diseases

Methodological Issues in Classifying Adjunct Anti Epileptic Drug (AED) treatment in claims data: Analysis of the effect of the minimum AED Co-administration period.

The Use of Quintile Analysis as a Measure of Disease Severity: A Comparison Within and Across Diseases

Migraine

Real World Objectively Measured Productivity Losses of Employees with Migraines and the Use of Calcitonin Gene-Related Peptide Inhibitors (CGRPis) in United States Employees

Characterizing Use and Productivity Losses Among United States Employees with Migraines Using Calcitonin Gene-Related Peptide inhibitors (CGRPis): 2017-2022

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Absence Benefit Utilization, Duration of Leaves, and Payments Vary By Benefit and over Time for Short- and Long-Term Disability and Workers’ Compensation for Employees with Headaches and Migraines in the United States

Multiple Sclerosis

The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis in the United States

Assessing Presence of MS-Related Symptoms as a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

Severity of Illness Among Persons with Multiple Sclerosis: An Analysis of Cost Quintiles.

The Impact of Multiple Sclerosis On Absenteeism

Absenteeism and Health Benefit Costs Among Employees with Multiple Sclerosis

Prevalence and Costs of Comorbidities Among Persons with and without Multiple Sclerosis: An Analysis of the AHRQ Major and Specific Diagnostic Categories

Medication adherence with Disease modifying treatments for multiple sclerosis: Findings from a US National database of employees

Health Benefit Costs Among Employees With Multiple Sclerosis.

Direct Medical Costs and the Likelihood of Health Service Utilization Before and After Initiation of Avonex (Interferon β1a IM) Treatment Among Persons with Multiple Sclerosis (MS)

Absenteeism (lost time) Among Employees with Multiple Sclerosis

Medication adherence with disease modifying treatments for multiple sclerosis among US employees

Comparing costs and absences for Multiple Sclerosis among US employees: pre- and post-treatment initiation

Musculoskeletal System and Connective Tissue

Self-reported and objectively measured productivity and absence costs for employees with back and joint disorders

Absence Time and Payments due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Musculoskeletal System Conditions

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Bone Diseases in the United States

Trends in Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Back Pain in the United States

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation For Employees with Rheumatoid Arthritis

Myotonic Dystrophy

Myotonic Dystrophy Patient Journey: Increased Use of Healthcare Resources in the Year Prior to Diagnosis as Evidenced by Insurance Claims

More Prevalent Comorbidities, Healthcare Costs, and Service Utilization in Male Myotonic Dystrophy (DM) Patients and Female Patients

Comparative Real‐World Retrospective Data Analysis of Comorbid Conditions and Healthcare Utilization for Patients with Myotonic Dystrophy Over a 5‐Year Timeframe

Specialty Pharmacy Products Used by Patients with Myotonic Dystrophy 2-Years Pre- and Post-Diagnosis

Myotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data Analysis

Specialists involved in the diagnosis and management of myotonic dystrophy based on a real-world data analysis pre- and post-diagnosis

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis  

Prescription Medications used by Patients with Myotonic Dystrophy Types 1 and 2 (DM) Prior to Diagnosis; a Real-World data analysis [Gold Ribbon]

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: a Real-World Data Analysis

Neurology

Myotonic Dystrophy Patient Journey: Increased Use of Healthcare Resources in the Year Prior to Diagnosis as Evidenced by Insurance Claims

The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity

Myotonic dystrophy, surgeries, cardiovascular testing, mobility aids and healthcare utilization based on a 5-year real-world data analysis

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Inpatient Admissions and Emergency Department Visits for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis of Pre- and Post-Diagnosis Events

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: a Real-World Data Analysis

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Understanding the Patients’ Journey to the Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis  

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Prescription medications during patients’ journey to the diagnosis of facioscapulohumeral muscular dystrophy: a real-world retrospective data analysis

Prescription Medications used by Patients with Myotonic Dystrophy Types 1 and 2 (DM) Prior to Diagnosis; a Real-World data analysis [Gold Ribbon]

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: a Real-World Data Analysis

Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Nervous System Disorders in the United States

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Absence Benefit Utilization, Duration of Leaves, and Payments Vary By Benefit and over Time for Short- and Long-Term Disability and Workers’ Compensation for Employees with Headaches and Migraines in the United States

The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis in the United States

Assessing Presence of MS-Related Symptoms as a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database

The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

Cost of illness for insomnia: medical, pharmacy, and work absence costs in employees with or without insomnia

Comparing costs and absences for Multiple Sclerosis among US employees: pre- and post-treatment initiation

Health Benefit Costs and Absenteeism due to Insomnia from the Employer’s Perspective

Medication adherence with disease modifying treatments for multiple sclerosis among US employees

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

Assessment of Work Absences Associated with Insomnia

Commonly used adjunctive therapies for persons with partial­ onset seizures

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. (ISPOR)

Comparisons of the Health Benefit Costs Among Monotherapy and Adjunctive Therapy Patients with Epilepsy and Their Employed Spouses

Comparisons of the utilization, costs, and services by location of care for employees whose spouses with epilepsy have partial onset seizures and are managed by monotherapy or adjunctive therapy.

Absenteeism and Health Benefit Costs Among Employees with Multiple Sclerosis

Cost, Absences, Prevalence and Impact of Bipolar Disorder, Other Mental Disorders, Chronic Constipation, Functional Dyspepsia, Gastroesophageal Reflux Disease, Gout, And Insomnia. (AMCP)

Direct Medical Costs and the Likelihood of Health Service Utilization Before and After Initiation of Avonex (Interferon β1a IM) Treatment Among Persons with Multiple Sclerosis (MS)

Health Benefit Costs Among Employees With Multiple Sclerosis.

Healthcare Cost Comparisons by Point-of-Service for Employees with or without Insomnia

Incremental Sick Leave Costs and Lost Time Among Employees with Psychiatric and Medical Conditions

Methodological Issues in Classifying Adjunct Anti Epileptic Drug (AED) treatment in claims data: Analysis of the effect of the minimum AED Co-administration period.

Objective Costs and Prevalence of Comorbidities for Persons with and without Insomnia

Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD

Prevalence and Costs of Comorbidities Among Persons with and without Multiple Sclerosis: An Analysis of the AHRQ Major and Specific Diagnostic Categories

Severity of Illness Among Persons with Multiple Sclerosis: An Analysis of Cost Quintiles.

The Impact of Multiple Sclerosis On Absenteeism

Obesity

Prevalence and Comorbid Condition Trends for Obesity Within US Self-Insured Employers

Prevalence and Comorbid Condition Trends for Obesity Within US Self-Insured Employers

Ophthalmology

Employer Disability and Workers’ Compensation Trends for Their Employees With Ophthalmic Conditions in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Eye (Ophthalmic) Conditions in the United States

United States comparative costs and absenteeism of diabetic ophthalmic conditions

Comparative Health Benefit Costs of Employees with Diabetic Macular Edema, Diabetic Retinopathy, or Diabetes Versus No Diabetes in the United States

How Does Diabetic Eye Disease Affect the American Worker?

Opioids

Work Absence and Absence Costs in Patients with Osteoarthritis (OA) and Low Back Pain (LBP) in the United States

Osteoarthritis

Work Absence and Absence Costs in Patients with Osteoarthritis (OA) and Low Back Pain (LBP) in the United States

Pain

Caregiver Trends in Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees Whose Spouses Have Back Pain in the United States

Absence Time and Payments due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Musculoskeletal System Conditions

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Bone Diseases in the United States

Trends in Leaves Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Back Pain in the United States

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation For Employees with Rheumatoid Arthritis

Work Absence and Absence Costs in Patients with Osteoarthritis (OA) and Low Back Pain (LBP) in the United States

A Healthcare Claims Database Analysis to Estimate the Prevalence of Chronic Opioid Use by Adult Patients in the United States

Add-back therapy use and its impact on LA persistence in patients with endometriosis

Chronic gout: epidemiology, disease progression, treatment and disease burden

The impact of gout on work absence and productivity

Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use

The economic burden of gout on an employed population

Lost Days and Productivity Impact of Gout

Payor

Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employees with Breast, Skin, GI, Female, Male, and “Other” Cancers

Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees With Cancer Conditions in the United States

Employer Paid Sick Leave, Disability, and Workers’ Compensation Trends for Employees Whose Spouses have Cancer Conditions in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Digestive System (Gastrointestinal) Conditions in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Systemic Lupus Erythematosus or Connective Tissue Disorders in the United States

Biosimilar adoption, benefit-use claims & dollars

Cancer caregiver absence cost and lost time

Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes, Depression, and Coronary Artery Disease

Integrated Data Models Outperform Direct Claims Only Models in Predicting New Mental Health Cases

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation For Employees with Rheumatoid Arthritis

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Osteoarthritis

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Mental Disorders in the United States

The Use of Comparative Effectiveness Research and Evidence Based Medicine in US Payor Decision Making

United States Health Plan Cancer Concerns in 2018

Constipation in a Medicaid population: Trends in prevalence, age, gender, and costs in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data

The United States Specialty Pharmacy Payor Landscape

The 2018 US Payor Landscape: Trends and Results from Formulary Management Surveys

The 2015 US Payor Landscape for Specialty Pharmacy: Results from a Survey of Medical and Pharmacy Directors.

The US Payor Landscape for Specialty Pharmacy: Results from a Survey of Medical and Pharmacy Directors

Survey Results of Contemporary US Health Plan Policies – Affordable Care Act (ACA), Digital Technologies, Value Based Contracting (VBC) and Comparative Effectiveness Research (CER)

Similarities between Constipation with and without Irritable Bowel Syndrome in a Medicaid population: Costs trends by category in the 12 months after diagnosis from 1997 to 2002 using a random sample of California Medicaid (Medi-Cal) data

Observations from U.S. Payors Today and Predictions for the Future

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Coverage and Reviews of Medical Devices, Laboratory and Diagnostic Testing By US Health Plans

Cost estimates of chronic constipation in California Medicaid (Medi-Cal) patients

Presenteeism

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Cancer

Self-reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders

Self-reported and objectively measured productivity and absence costs for employees with back and joint disorders

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Cancer

Self-reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

Impact of Rheumatoid Arthritis on Health Care Costs and Work Productivity: A Comparative Assessment With Diabetes and Depression 

Lost Days and Productivity Impact of Gout

Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD

Objective Measurement of Productivity While at Work in US Employees with and without Gastroesophageal Reflux Disease (GERD)

The Impact of Hepatitis-C Viral (HCV) Treatment on Work Absence and Productivity

Prostate Cancer

Persistence with Leuprolide Acetate in patients with Prostate Cancer

Pulmonary

An employer perspective on annual employee and dependent costs for pediatric asthma

Exploratory Economic Evaluation of Patients With COPD on a Combination Product Versus Individual Components (Ipratropium Bromide and Albuterol)

A Retrospective Economic Comparison of Combined Ipratroprium Bromide and Albuterol versus Individual Components in Chronic Obstructive Pulmonary Disease (COPD) Patients

Pediatric Asthma: An Employer Perspective on Annual Employee and Dependent Costs for Medical Care and Prescription Drugs

Pulmonology

Trends in Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers’ Compensation for Employees with Respiratory Conditions

Exploratory Economic Evaluation of Patients With COPD on a Combination Product Versus Individual Components (Ipratropium Bromide and Albuterol)

Cost-minimization Analysis of Treatment for Respiratory Distress Syndrome

Cost-minimization Analysis of Two Surfactant Treatments for Respiratory Distress Syndrome (ASHP)

Pediatric Asthma: An Employer Perspective on Annual Employee and Dependent Costs for Medical Care and Prescription Drugs

Rare Disease

Myotonic Dystrophy Patient Journey: Increased Use of Healthcare Resources in the Year Prior to Diagnosis as Evidenced by Insurance Claims

More Prevalent Comorbidities, Healthcare Costs, and Service Utilization in Male Myotonic Dystrophy (DM) Patients and Female Patients

Sex-related Utilization Differences in the 12-months After a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral Muscular Dystrophy (FSHD) Age-Related Differences in Management Among Patients Over and Under 40 Years

Facioscapulohumeral Muscular Dystrophy (FSHD) Mobility Aids and Healthcare Utilization After Diagnosis from a Real-World Data Analysis

Comparative Real‐World Retrospective Data Analysis of Comorbid Conditions and Healthcare Utilization for Patients with Myotonic Dystrophy Over a 5‐Year Timeframe

Prescription Medication Use Prior to and Following a Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): Learnings from the Patient Journey

Specialty Pharmacy Products Used by Patients with Myotonic Dystrophy 2-Years Pre- and Post-Diagnosis

Myotonic Dystrophy, Comorbid Conditions and Healthcare Utilization Based on a 5-Year Comparative Real-World Data Analysis

Specialists involved in the diagnosis and management of myotonic dystrophy based on a real-world data analysis pre- and post-diagnosis

Myotonic dystrophy, surgeries, cardiovascular testing, mobility aids and healthcare utilization based on a 5-year real-world data analysis

Inpatient Admissions and Emergency Department Visits for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD): A Real-World Retrospective Data Analysis of Pre- and Post-Diagnosis Events

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: a Real-World Data Analysis

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Understanding the Patients’ Journey to the Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM1 and DM2) Prior to Diagnosis: a Real-World Data Analysis  

Prescription medications during patients’ journey to the diagnosis of facioscapulohumeral muscular dystrophy: a real-world retrospective data analysis

Prescription Medications used by Patients with Myotonic Dystrophy Types 1 and 2 (DM) Prior to Diagnosis; a Real-World data analysis [Gold Ribbon]

Understanding the Patients’ Journey Pre‑ and Post-Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD): a Real-World Retrospective Data Analysis

Prevalence of Healthcare Conditions and Services Used by Patients with Myotonic Dystrophy (DM) Pre- and Post-Diagnosis: a Real-World Data Analysis

Renal

The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia

Reproductive Health

Real World Retrospective Analysis of Short-term Disability Claims for Genitourinary System Conditions in the United States

Real World Retrospective Analysis of Short-Term Disability Claims for the Genitourinary System in the United States

The Impact of Health Benefit Design on Assisted Reproductive Technology (ART) Utilization and Pregnancy-Related Outcomes

Rheumatology

Rheumatoid Arthritis Disability and Absence Trends in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Systemic Lupus Erythematosus or Connective Tissue Disorders in the United States

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation For Employees with Rheumatoid Arthritis

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Osteoarthritis

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database

Cost comparisons by place of service for persons with and without gout

Objective measurement of hourly and annual productivity while at work in employees with Gastroesophageal Reflux Disease (GERD) compared with employees without GERD

Lost Days and Productivity Impact of Gout

Impact of Rheumatoid Arthritis on Health Care Costs and Work Productivity: A Comparative Assessment With Diabetes and Depression 

Economic Burden of Gout to the Employer

Cost, Absences, Prevalence and Impact of Bipolar Disorder, Other Mental Disorders, Chronic Constipation, Functional Dyspepsia, Gastroesophageal Reflux Disease, Gout, And Insomnia. (AMCP)

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Annual Objective Productivity (Presenteeism) Across Several Diseases: Bipolar Disorders, Chronic Constipation, Functional Dyspepsia, GERD, Gout, and Insomnia

A comparison of average annual medical services for comorbid conditions associated with metabolic syndrome found in employees with gout versus those without gout

The economic burden of gout on an employed population

Metabolic syndrome-related conditions among people with and without gout: prevalence and resource use

The impact of gout on work absence and productivity

Chronic gout: epidemiology, disease progression, treatment and disease burden

Annual Incremental Health Benefit Costs and Absenteeism Among Employees with and Without Rheumatoid Arthritis

Skin Conditions

Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Cost, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions

Specialty

NASP 2023 Annual Meeting ReCap Show (Part Three)

Biosimilar Benefit Use, Adoption, and Conversions

Biologic, Biosimilar and Specialty Drug Utilization Trends Among US Employers

2021 National Association of Specialty Pharmacy: Research Presentation Abstracts

Costs and absence of HCV-infected employees by disease stage

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Management of Specialty Drugs, Specialty Pharmacies and Biosimilars in the United States

Management of Specialty Pharmacies, Specialty and Biosimilar products 

Specialty pharmaceuticals and the quest for better outcomes

Specialty Pharmacy, Diagnostic and Genetic Testing Coverage in US Health Plans: Results from a Survey of Medical and Pharmacy Directors

The 2015 US Payor Landscape for Specialty Pharmacy: Results from a Survey of Medical and Pharmacy Directors.

The United States Specialty Pharmacy Payor Landscape

SUD (Substance Use Disorders)

Disability and workers’ compensation trends for employees with mental disorders and SUDs in the United States

Long- and Short-Term Disability and Workers’ Compensation Trends for Employees with Substance Abuse Mental Disorders in the United States

urology

Real World Retrospective Analysis of Short-Term Disability Claims for the Genitourinary System in the United States

Virology

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database

Absenteeism and Productivity Among Employees Being Treated for Hepatitis C

The Impact of Hepatitis-C Viral (HCV) Infection on Work Absence, Productivity, and Healthcare Benefit Costs

Comparison of Direct Medical Costs and Services by Point of Service and Prescription Cost for Persons With Hepatitis-C With and Without Treatment

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Employee Workers’ Compensation Costs and Absence Days Using a National Database. (ISPOR)

Comparisons of Relative Risks of Serious Comorbidities Among Employees with and without Insomnia, GERD, Hepatitis C, Multiple Sclerosis and Chronic Constipation. (ISPOR)

Costs and absence of HCV-infected employees by disease stage

Employees Living with Human Immunodeficiency Virus (HIV): Impact of Disease and Antiretroviral Therapies on Healthcare Costs and Productivity

The Direct and Indirect Costs of Employees with Hepatitis C Vary by Stage of Disease. Presented at Academy Health’s 2014 Annual Research Meeting

The Impact of Hepatitis-C Viral (HCV) Treatment on Work Absence and Productivity

Womens Health

Real World Retrospective Analysis of Short-term Disability Claims for Genitourinary System Conditions in the United States

Real World Retrospective Analysis of Short-Term Disability Claims for the Genitourinary System in the United States

Add-back therapy use and its impact on LA persistence in patients with endometriosis